

Bernhard Scheiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4743417/publications.pdf>

Version: 2024-02-01

126
papers

3,171
citations

185998

28
h-index

189595

50
g-index

127
all docs

127
docs citations

127
times ranked

3000
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	2.4	12
2	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	6.1	19
3	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	2.4	25
4	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	1.8	7
5	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	2.4	39
6	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
7	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.4	11
8	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
9	Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection. <i>Journal of Hepatology</i> , 2022, , .	1.8	2
10	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59
11	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	1.4	43
12	Reply to: “The CRAFTY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy”. <i>Journal of Hepatology</i> , 2022, 76, 1233-1234.	1.8	1
13	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	1.1	5
14	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. <i>Cancers</i> , 2022, 14, 1722.	1.7	26
15	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
16	Reply to: “Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?”. <i>Journal of Hepatology</i> , 2022, 76, 988-989.	1.8	0
17	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
18	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	2.3	11

#	ARTICLE	IF	CITATIONS
19	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	1.9	15
20	Reply to: "The CRAFTY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations" <i>Journal of Hepatology</i> , 2022, , .	1.8	0
21	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	3.6	45
22	On coagulation in advanced chronic liver disease and the origin of freshwater eels. <i>Journal of Hepatology</i> , 2022, 77, 886-887.	1.8	1
23	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	2.0	6
24	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	1.9	16
25	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	6.1	51
26	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	6.1	150
27	Alpha-fetoprotein-adjusted HCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 209-219.	1.6	5
28	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	3.6	45
29	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	1.8	96
30	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.4	0
31	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	1.9	27
32	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	4.2	25
33	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
34	Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease. <i>PLoS ONE</i> , 2021, 16, e0249785.	1.1	6
35	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	1.1	5
36	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	1.6	22

#	ARTICLE	IF	CITATIONS
37	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	1.9	12
38	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	2.0	16
39	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	1.9	36
40	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	1.1	16
41	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 723-732.	0.2	105
42	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, .		0
43	Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
44	Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy - the CRAFT score. , 2021, 59, .		0
45	Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
46	Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
47	Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
48	NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death. , 2021, 59, .		0
49	The link between bacterial translocation, systemic inflammation, and circulatory dysfunction in cirrhosis. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
50	Safety and efficacy of direct oral anticoagulants (DOACs) in Budd-Chiari Syndrome (BCS) - an Austrian multicenter study. , 2021, 59, .		0
51	Antibiotic therapy is associated with worse outcome in patients with hepatocellular carcinoma treated with sorafenib. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
52	Immunoglobulin subtypes and complement levels exhibit distinct dynamics across advanced chronic liver disease stages and predict first or further decompensation. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
53	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. , 2021, 59, .		0
54	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	1.1	10
56	Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
57	The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
58	Increasing ACE activity in liver disease impacts on fibrinolysis and inflammation - a potential link to COVID-19. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
59	Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
60	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	1.9	45
61	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.0	15
62	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2712-2718.	1.1	4
63	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 533-542.	2.3	18
64	Impact of <i>HSD17B13 rs72613567</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	1.9	20
65	Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma". <i>Liver Cancer</i> , 2020, 9, 107-107.	4.2	0
66	Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?". <i>Liver Cancer</i> , 2020, 9, 110-111.	4.2	0
67	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	1.7	8
68	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , 2020, 14, 1083-1092.	1.9	9
69	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>BMC Medicine</i> , 2020, 18, 336.	2.3	5
70	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.4	6
71	Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 917-918.	1.9	0
72	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	1.7	47

#	ARTICLE	IF	CITATIONS
73	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	1.9	12
74	Noninvasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	1.9	14
75	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	1.9	17
76	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	1.9	21
77	Novel reliability criteria for controlled attenuation parameter assessments for noninvasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	1.6	30
78	Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16668-e16668.	0.8	5
79	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.2	0
80	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	1.9	39
81	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , 2019, 9, 11674.	1.6	6
82	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	1.6	18
83	Letter: programmed cell death protein-1 targeted immunotherapy for advanced hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 341-342.	1.9	0
84	Letter: programmed cell death protein-1 (PD-1) targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort—more questions than answers. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 231-232.	1.9	5
85	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	1.1	10
86	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 395-403.	1.0	13
87	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 714-726.	1.9	49
88	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	1.1	8
89	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	1.4	9
90	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	1.1	10

#	ARTICLE	IF	CITATIONS
91	High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterology Journal, 2019, 7, 507-516.	1.6	22
92	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Digestive and Liver Disease, 2019, 51, 1144-1151.	0.4	23
93	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterology Journal, 2019, 7, 651-661.	1.6	7
94	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	1.9	106
95	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 203-217.	4.2	48
96	PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort. , 2019, 57, .		0
97	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
98	Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. , 2019, 57, .		0
99	Reliability criteria for controlled attenuation parameter (CAP) for assessing hepatic steatosis using transient elastography. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
100	Prevalence of and risk factors for anemia in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
101	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
102	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	2.4	127
103	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Alimentary Pharmacology and Therapeutics, 2018, 47, 966-979.	1.9	41
104	Reply to: "Acid-base disorders in liver disease". Journal of Hepatology, 2018, 68, 618-619.	1.8	1
105	Transferrin as a predictor of survival in cirrhosis. Liver Transplantation, 2018, 24, 343-351.	1.3	27
106	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. Wiener Klinische Wochenschrift, 2018, 130, 105-114.	1.0	14
107	Editorial: surviving your genes—the role of PNPLA3 variation in end-stage liver disease. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 775-776.	1.9	0
108	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound in Medicine and Biology, 2018, 44, 2578-2586.	0.7	11

#	ARTICLE	IF	CITATIONS
109	Impact of patatinâ€like phospholipase domain containing <i>3 rs738409</i> G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 451-459.	1.9	26
110	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.0	41
111	Controlled attenuation parameter (CAPâ€) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.2	0
112	The impact of hepatic steatosis on portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.2	0
113	Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis. , 2018, 56, .		0
114	Limited diagnostic performance of controlled attenuation parameter for assessing hepatic steatosis in patients with advanced chronic liver disease and portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.2	0
115	Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information. , 2018, 56, .		0
116	Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.2	0
117	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , 2018, 56, .		0
118	Interferonâ€free regimens improve portal hypertension and histological necroinflammation in <scp>HIV</scp>/<scp>HCV</scp> patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 139-149.	1.9	83
119	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	0.6	13
120	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.0	9
121	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1062-1073.	1.8	67
122	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	1.0	42
123	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	0.4	18
124	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	1.1	23
125	Healthâ€related quality of life and severity of fatigue in <scp>HIV</scp>/<scp>HCV</scp> coâ€infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	1.9	35
126	Immune-related hepatitis in aâ€patient with hepatocellular carcinoma treated with nivolumab. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	2